Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

SLDE vs UPC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SLDE
Slide Insurance Holdings, Inc. Common Stock

Insurance - Property & Casualty

Financial ServicesNASDAQ • US
Market Cap$2.14B
5Y Perf.-13.5%
UPC
Universe Pharmaceuticals Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CN
Market Cap$2M
5Y Perf.-24.8%

SLDE vs UPC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SLDE logoSLDE
UPC logoUPC
IndustryInsurance - Property & CasualtyDrug Manufacturers - Specialty & Generic
Market Cap$2.14B$2M
Revenue (TTM)$1.26B$41M
Net Income (TTM)$491M$-12M
Gross Margin81.5%30.3%
Operating Margin51.5%-26.7%
Forward P/E5.3x
Total Debt$0.00$9M
Cash & Equiv.$34M

SLDE vs UPCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SLDE
UPC
StockJun 25May 26Return
Slide Insurance Hol… (SLDE)10086.5-13.5%
Universe Pharmaceut… (UPC)10075.2-24.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: SLDE vs UPC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SLDE leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
SLDE
Slide Insurance Holdings, Inc. Common Stock
The Insurance Pick

SLDE carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 0.59
  • Rev growth 36.5%, EPS growth 108.7%, 3Y rev CAGR 68.3%
  • -7.5% 10Y total return vs UPC's -100.0%
Best for: income & stability and growth exposure
UPC
Universe Pharmaceuticals Inc.
The Specific-Use Pick

In this particular matchup, UPC is outpaced on most metrics by others in the set.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthSLDE logoSLDE36.5% revenue growth vs UPC's -22.4%
Quality / MarginsSLDE logoSLDE38.9% margin vs UPC's -30.3%
Stability / SafetySLDE logoSLDEBeta 0.59 vs UPC's 1.26
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)SLDE logoSLDE-7.5% vs UPC's -36.9%
Efficiency (ROA)SLDE logoSLDE23.9% ROA vs UPC's -18.6%

SLDE vs UPC — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSLDELAGGINGUPC

Income & Cash Flow (Last 12 Months)

SLDE leads this category, winning 6 of 6 comparable metrics.

SLDE is the larger business by revenue, generating $1.3B annually — 30.9x UPC's $41M. SLDE is the more profitable business, keeping 38.9% of every revenue dollar as net income compared to UPC's -30.3%. On growth, SLDE holds the edge at +38.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSLDE logoSLDESlide Insurance H…UPC logoUPCUniverse Pharmace…
RevenueTrailing 12 months$1.3B$41M
EBITDAEarnings before interest/tax$645M-$10M
Net IncomeAfter-tax profit$491M-$12M
Free Cash FlowCash after capex$987M-$15M
Gross MarginGross profit ÷ Revenue+81.5%+30.3%
Operating MarginEBIT ÷ Revenue+51.5%-26.7%
Net MarginNet income ÷ Revenue+38.9%-30.3%
FCF MarginFCF ÷ Revenue+78.1%-37.2%
Rev. Growth (YoY)Latest quarter vs prior year+38.2%-14.1%
EPS Growth (YoY)Latest quarter vs prior year+37.8%-100.1%
SLDE leads this category, winning 6 of 6 comparable metrics.

Valuation Metrics

UPC leads this category, winning 2 of 2 comparable metrics.
MetricSLDE logoSLDESlide Insurance H…UPC logoUPCUniverse Pharmace…
Market CapShares × price$2.1B$2M
Enterprise ValueMkt cap + debt − cash$2.1B-$23M
Trailing P/EPrice ÷ TTM EPS5.58x-0.00x
Forward P/EPrice ÷ next-FY EPS est.5.29x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple3.66x
Price / SalesMarket cap ÷ Revenue1.86x0.09x
Price / BookPrice ÷ Book value/share0.00x
Price / FCFMarket cap ÷ FCF2.70x
UPC leads this category, winning 2 of 2 comparable metrics.

Profitability & Efficiency

SLDE leads this category, winning 4 of 6 comparable metrics.

SLDE delivers a 66.7% return on equity — every $100 of shareholder capital generates $67 in annual profit, vs $-27 for UPC. On the Piotroski fundamental quality scale (0–9), UPC scores 4/9 vs SLDE's 3/9, reflecting mixed financial health.

MetricSLDE logoSLDESlide Insurance H…UPC logoUPCUniverse Pharmace…
ROE (TTM)Return on equity+66.7%-27.0%
ROA (TTM)Return on assets+23.9%-18.6%
ROICReturn on invested capital-7.8%
ROCEReturn on capital employed-5.6%
Piotroski ScoreFundamental quality 0–934
Debt / EquityFinancial leverage0.16x
Net DebtTotal debt minus cash$0-$24M
Cash & Equiv.Liquid assets$34M
Total DebtShort + long-term debt$0$9M
Interest CoverageEBIT ÷ Interest expense184.25x-22.11x
SLDE leads this category, winning 4 of 6 comparable metrics.

Total Returns (Dividends Reinvested)

SLDE leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in SLDE five years ago would be worth $9,254 today (with dividends reinvested), compared to $2 for UPC. Over the past 12 months, SLDE leads with a -7.5% total return vs UPC's -36.9%. The 3-year compound annual growth rate (CAGR) favors SLDE at -2.6% vs UPC's -89.5% — a key indicator of consistent wealth creation.

MetricSLDE logoSLDESlide Insurance H…UPC logoUPCUniverse Pharmace…
YTD ReturnYear-to-date+1.0%-32.2%
1-Year ReturnPast 12 months-7.5%-36.9%
3-Year ReturnCumulative with dividends-7.5%-99.9%
5-Year ReturnCumulative with dividends-7.5%-100.0%
10-Year ReturnCumulative with dividends-7.5%-100.0%
CAGR (3Y)Annualised 3-year return-2.6%-89.5%
SLDE leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

SLDE leads this category, winning 2 of 2 comparable metrics.

SLDE is the less volatile stock with a 0.59 beta — it tends to amplify market swings less than UPC's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SLDE currently trades 72.4% from its 52-week high vs UPC's 25.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSLDE logoSLDESlide Insurance H…UPC logoUPCUniverse Pharmace…
Beta (5Y)Sensitivity to S&P 5000.59x1.26x
52-Week HighHighest price in past year$25.90$11.00
52-Week LowLowest price in past year$12.53$2.00
% of 52W HighCurrent price vs 52-week peak+72.4%+25.7%
RSI (14)Momentum oscillator 0–10052.651.5
Avg Volume (50D)Average daily shares traded2.2M8K
SLDE leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricSLDE logoSLDESlide Insurance H…UPC logoUPCUniverse Pharmace…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$26.00
# AnalystsCovering analysts4
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises2
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+1.9%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

SLDE leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). UPC leads in 1 (Valuation Metrics).

Best OverallSlide Insurance Holdings, I… (SLDE)Leads 4 of 6 categories
Loading custom metrics...

SLDE vs UPC: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is SLDE or UPC a better buy right now?

For growth investors, Slide Insurance Holdings, Inc.

Common Stock (SLDE) is the stronger pick with 36. 5% revenue growth year-over-year, versus -22. 4% for Universe Pharmaceuticals Inc. (UPC). Slide Insurance Holdings, Inc. Common Stock (SLDE) offers the better valuation at 5. 6x trailing P/E (5. 3x forward), making it the more compelling value choice. Analysts rate Slide Insurance Holdings, Inc. Common Stock (SLDE) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — SLDE or UPC?

Over the past 5 years, Slide Insurance Holdings, Inc.

Common Stock (SLDE) delivered a total return of -7. 5%, compared to -100. 0% for Universe Pharmaceuticals Inc. (UPC). Over 10 years, the gap is even starker: SLDE returned -7. 5% versus UPC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — SLDE or UPC?

By beta (market sensitivity over 5 years), Slide Insurance Holdings, Inc.

Common Stock (SLDE) is the lower-risk stock at 0. 59β versus Universe Pharmaceuticals Inc. 's 1. 26β — meaning UPC is approximately 115% more volatile than SLDE relative to the S&P 500.

04

Which is growing faster — SLDE or UPC?

By revenue growth (latest reported year), Slide Insurance Holdings, Inc.

Common Stock (SLDE) is pulling ahead at 36. 5% versus -22. 4% for Universe Pharmaceuticals Inc. (UPC). On earnings-per-share growth, the picture is similar: Slide Insurance Holdings, Inc. Common Stock grew EPS 108. 7% year-over-year, compared to 26. 5% for Universe Pharmaceuticals Inc.. Over a 3-year CAGR, SLDE leads at 68. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — SLDE or UPC?

Slide Insurance Holdings, Inc.

Common Stock (SLDE) is the more profitable company, earning 38. 4% net margin versus -20. 6% for Universe Pharmaceuticals Inc. — meaning it keeps 38. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLDE leads at 51. 0% versus -16. 3% for UPC. At the gross margin level — before operating expenses — SLDE leads at 79. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — SLDE or UPC?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is SLDE or UPC better for a retirement portfolio?

For long-horizon retirement investors, Slide Insurance Holdings, Inc.

Common Stock (SLDE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 59)). Both have compounded well over 10 years (SLDE: -7. 5%, UPC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between SLDE and UPC?

These companies operate in different sectors (SLDE (Financial Services) and UPC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SLDE is a small-cap high-growth stock; UPC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

SLDE

High-Growth Quality Leader

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 19%
  • Net Margin > 23%
Run This Screen
Stocks Like

UPC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 18%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SLDE and UPC on the metrics below

Revenue Growth>
%
(SLDE: 38.2% · UPC: -14.1%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.